BioCryst’s Oral Factor D Inhibitor, BCX9930, Shows Clinical Benefit as Monotherapy Through 400 mg bid in Treatment-naïve PNH Patients

NEXT STORY
OpGen Announces Award of German Government Grant Funding to its Subsidiary Curetis and Collaborators
PREV STORY
Global Medical Gowns Market Outlook & Forecast Report 2020-2025: Market is Expected to Observe an Absolute Growth of 69%
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval

                                                   --   Vifor Pharma Commits to Exclusive Distribution of Vadadustat to Fresenius Medical Care North America ...

author_avatar
NASDAQ Market News

Rockwell Medical Enters Into Exclusive License Agreement With Wanbang Biopharmaceutical Co., Ltd. to Commercialize Triferic® in China

WIXOM, Mich., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated ...

author_avatar
NASDAQ Market News

Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2018 Financial Results

NEW YORK, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a ...

author_avatar
NASDAQ Market News